ONC
BeiGene, Ltd.
NASDAQ: ONC · HEALTHCARE · BIOTECHNOLOGY
$295.27
+1.54% today
Updated 2026-04-30
Market cap
$33.18B
P/E ratio
120.52
P/S ratio
6.21x
EPS (TTM)
$2.48
Dividend yield
—
52W range
$218 – $385
Volume
0.2M
BeiGene, Ltd. (ONC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
5.37%
Operating margin
12.30%
ROE
7.46%
ROA
3.96%
Debt/equity
0.25x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $11.15M | $-7.49M | -20.77% | -48.96% | -67.22% |
| 2014 | $13.04M | $-18.28M | -67.72% | -120.88% | -140.22% |
| 2015 | $8.82M | $-57.10M | -560.73% | -643.66% | -647.71% |
| 2016 | $1.07M | $-119.22M | -9,061.96% | -10,940.19% | -11,141.78% |
| 2017 | $238.39M | $-93.11M | -14.94% | -41.30% | -39.06% |
| 2018 | $198.22M | $-673.77M | -257.03% | -356.05% | -339.91% |
| 2019 | $428.21M | $-948.63M | 83.38% | -224.16% | -221.53% |
| 2020 | $308.87M | $-1.62B | 77.12% | -536.69% | -526.10% |
| 2021 | $1.18B | $-1.46B | 85.98% | -122.31% | -123.93% |
| 2022 | $1.42B | $-2.00B | 79.77% | -126.40% | -141.52% |
| 2023 | $2.46B | $-881.71M | 84.55% | -49.12% | -35.86% |
| 2024 | $3.81B | $-644.79M | 84.41% | -14.91% | -16.92% |
| 2025 | $5.34B | $286.93M | 87.49% | 8.37% | 5.37% |